Predictors of lethal outcome in patients with immunoinflammatory diseases hospitalized in the intensive care unit

Table 2 The features, treatment, and outcomes of the patients with different immune-mediated diseases admitted to the intensive care unit

Parameter	MIS-C (n = 18)	SRD (n = 24)	Infections (n = 9)	P value
Demography
Sex, males	11 (61.1)	8 (33.3)	4 (44.4)	0.201
Age, months, median (25%; 75%)	106 (64; 137)	175 (115; 193)	41 (19; 60)	0.001
Time from the hospital to ICU admission, days, median (25%; 75%)	6 (4; 10)	30 (3; 28)	7 (7; 8)	0.00001
Preceding IST	2 (11.1)	10 (41.1)	2 (22.2)	0.083
Treatment
New IST	16 (88.9)	9 (37.5)	4 (44.4)	0.003
Follow-up IST	18 (100.0)	19 (79.2)	6 (66.7)	0.051
Intravenous immunoglobulin	5 (27.8)	11 (45.8)	4 (44.4)	0.465
Biological treatment	3 (16.7)	3 (12.5)	2 (22.2)	0.784
Outcomes
Total hospital staying, days, median (25%; 75%)	17 (14; 26)	28 (19; 68)	32 (25; 50)	0.013
Duration of stay in ICU, days, median (25%; 75%)	6 (4; 10)	7 (4; 23)	9 (5; 24)	0.534
Invasive mycosis	0 (0)	6 (25)	0 (0)	0.022
Fatal outcome	1 (7.7)	10 (41.7)	2 (15.4)	0.028
Time since ICU admission to dearth, days, median (25%; 75%)	46 (46; 46)	25 (9; 62)	57 (39; 75)	0.544

Data presented as n (%). MIS-C: Multisystem inflammatory syndrome associated with COVID-19 in children; SRD: Systemic rheumatic diseases; ICU: Intensive care unit; IST: Immune-suppressive treatment.